Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Muraglitazar · 9 trials · 8 indications
| Name | Type | Description |
|---|---|---|
| Muraglitazar | DRUG | - |
| Pioglitazone | DRUG | - |
Inclusion Criteria: * Type 2 Diabetes * HbA1c \> = 8.0% and \< = 12.0% * Serum triglyceride concentration \< = 600 mg/dL * Fasting c-peptide \> = 1.0 ng/ml * Body mass index \< = 41 kg/m2 * Drug naive patients Exclusion Criteria: * History of MI (myocardial infarction), coronary angioplasty or by...
Muraglitazar is an investigational oral small molecule developed by Bristol-Myers Squibb for type 2 diabetes and dyslipidemia. It was studied as a dual PPAR agonist, a single agent designed to act on both PPARG and PPARA. It is not an approved medicine; all of its clinical trials have been completed.
Muraglitazar targets PPARG and PPARA, two nuclear receptors that regulate glucose and lipid metabolism. It acts as an agonist at both receptors, which is why it is described as a dual PPAR agonist. This dual activity was studied for effects on glycemic control and lipid levels in people with type 2 diabetes and dyslipidemia.
Muraglitazar was developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The compound also appears in the literature and trial records under the code name BMS-298585. Bristol-Myers Squibb sponsored the clinical program evaluating it in type 2 diabetes and dyslipidemia.
Muraglitazar reached Phase 3 clinical development. It is investigational and has not been approved for any indication. Three completed trials are listed, including two Phase 3 studies and two Phase 2 studies, with a combined enrollment of 3,234 participants. No trials are currently active.
Completed trials include NCT00246987, a Phase 3 monotherapy study in type 2 diabetes with 341 participants, and NCT00240370, a Phase 3 study combining Muraglitazar or pioglitazone with metformin in 1,159 participants. Phase 2 studies were NCT00245388 in mixed dyslipidemia and NCT00240383, a dose-ranging monotherapy trial in type 2 diabetes.
Yes. Muraglitazar is the same compound as BMS-298585, the internal Bristol-Myers Squibb code used in its clinical trial titles. Records for the monotherapy Phase 3 trial in type 2 diabetes and the Phase 2 dyslipidemia trial refer to the drug as BMS-298585, while other studies use the name Muraglitazar.